CovidChloroV1, Main, Corpus, bibRecord, 001251

Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.

Identifieur interne : 001251 ( Main/Corpus ); précédent : 001250; suivant : 001252

Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.

Auteurs : Delia Bishara ; Chris Kalafatis ; David Taylor

Source :

Therapeutic advances in psychopharmacology [ 2045-1253 ] ; 2020.

RBID : pubmed:32612804

Abstract

As yet, no agents have been approved for the treatment of COVID-19, although several experimental drugs are being used off licence. These may have serious adverse effects and potential drug interactions with psychotropic agents. We reviewed the common agents being used across the world for the treatment of COVID-19 and investigated their drug interaction potential with psychotropic agents using several drug interaction databases and resources. A preliminary search identified the following drugs as being used to treat COVID-19 symptoms: atazanavir (ATV), azithromycin (AZI), chloroquine (CLQ)/hydroxychloroquine (HCLQ), dipyridamole, famotidine (FAM), favipiravir, lopinavir/ritonavir (LPV/r), nitazoxanide, remdesivir, ribavirin and tocilizumab. Many serious adverse effects and potential drug interactions with psychotropic agents were identified. The most problematic agents were found to be ATV, AZI, CLQ, HCLQ, FAM and LPV/r in terms of both pharmacokinetic as well as serious pharmacodynamic drug interactions, including QTc prolongation and neutropenia. Significant caution should be exercised if using any of the medications being trialled for the treatment of COVID-19 until robust clinical trial data are available. An even higher threshold of vigilance should be maintained for patients with pre-existing conditions and older adults due to added toxicity and drug interactions, especially with psychotropic agents.

DOI: 10.1177/2045125320935306
PubMed: 32612804
PubMed Central: PMC7309390

Links to Exploration step

pubmed:32612804

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.</title>
<author><name sortKey="Bishara, Delia" sort="Bishara, Delia" uniqKey="Bishara D" first="Delia" last="Bishara">Delia Bishara</name>
<affiliation><nlm:affiliation>Maudsley Hospital, Denmark Hill, Camberwell, London SE5 8AZ, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kalafatis, Chris" sort="Kalafatis, Chris" uniqKey="Kalafatis C" first="Chris" last="Kalafatis">Chris Kalafatis</name>
<affiliation><nlm:affiliation>South London and Maudsley NHS Foundation Trust, London, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Taylor, David" sort="Taylor, David" uniqKey="Taylor D" first="David" last="Taylor">David Taylor</name>
<affiliation><nlm:affiliation>South London and Maudsley NHS Foundation Trust, London, UK.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32612804</idno>
<idno type="pmid">32612804</idno>
<idno type="doi">10.1177/2045125320935306</idno>
<idno type="pmc">PMC7309390</idno>
<idno type="wicri:Area/Main/Corpus">001251</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001251</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.</title>
<author><name sortKey="Bishara, Delia" sort="Bishara, Delia" uniqKey="Bishara D" first="Delia" last="Bishara">Delia Bishara</name>
<affiliation><nlm:affiliation>Maudsley Hospital, Denmark Hill, Camberwell, London SE5 8AZ, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kalafatis, Chris" sort="Kalafatis, Chris" uniqKey="Kalafatis C" first="Chris" last="Kalafatis">Chris Kalafatis</name>
<affiliation><nlm:affiliation>South London and Maudsley NHS Foundation Trust, London, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Taylor, David" sort="Taylor, David" uniqKey="Taylor D" first="David" last="Taylor">David Taylor</name>
<affiliation><nlm:affiliation>South London and Maudsley NHS Foundation Trust, London, UK.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Therapeutic advances in psychopharmacology</title>
<idno type="ISSN">2045-1253</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As yet, no agents have been approved for the treatment of COVID-19, although several experimental drugs are being used off licence. These may have serious adverse effects and potential drug interactions with psychotropic agents. We reviewed the common agents being used across the world for the treatment of COVID-19 and investigated their drug interaction potential with psychotropic agents using several drug interaction databases and resources. A preliminary search identified the following drugs as being used to treat COVID-19 symptoms: atazanavir (ATV), azithromycin (AZI), chloroquine (CLQ)/hydroxychloroquine (HCLQ), dipyridamole, famotidine (FAM), favipiravir, lopinavir/ritonavir (LPV/r), nitazoxanide, remdesivir, ribavirin and tocilizumab. Many serious adverse effects and potential drug interactions with psychotropic agents were identified. The most problematic agents were found to be ATV, AZI, CLQ, HCLQ, FAM and LPV/r in terms of both pharmacokinetic as well as serious pharmacodynamic drug interactions, including QTc prolongation and neutropenia. Significant caution should be exercised if using any of the medications being trialled for the treatment of COVID-19 until robust clinical trial data are available. An even higher threshold of vigilance should be maintained for patients with pre-existing conditions and older adults due to added toxicity and drug interactions, especially with psychotropic agents.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32612804</PMID>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2045-1253</ISSN>
<JournalIssue CitedMedium="Print"><Volume>10</Volume>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Therapeutic advances in psychopharmacology</Title>
<ISOAbbreviation>Ther Adv Psychopharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.</ArticleTitle>
<Pagination><MedlinePgn>2045125320935306</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/2045125320935306</ELocationID>
<Abstract><AbstractText>As yet, no agents have been approved for the treatment of COVID-19, although several experimental drugs are being used off licence. These may have serious adverse effects and potential drug interactions with psychotropic agents. We reviewed the common agents being used across the world for the treatment of COVID-19 and investigated their drug interaction potential with psychotropic agents using several drug interaction databases and resources. A preliminary search identified the following drugs as being used to treat COVID-19 symptoms: atazanavir (ATV), azithromycin (AZI), chloroquine (CLQ)/hydroxychloroquine (HCLQ), dipyridamole, famotidine (FAM), favipiravir, lopinavir/ritonavir (LPV/r), nitazoxanide, remdesivir, ribavirin and tocilizumab. Many serious adverse effects and potential drug interactions with psychotropic agents were identified. The most problematic agents were found to be ATV, AZI, CLQ, HCLQ, FAM and LPV/r in terms of both pharmacokinetic as well as serious pharmacodynamic drug interactions, including QTc prolongation and neutropenia. Significant caution should be exercised if using any of the medications being trialled for the treatment of COVID-19 until robust clinical trial data are available. An even higher threshold of vigilance should be maintained for patients with pre-existing conditions and older adults due to added toxicity and drug interactions, especially with psychotropic agents.</AbstractText>
<CopyrightInformation>© The Author(s), 2020.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bishara</LastName>
<ForeName>Delia</ForeName>
<Initials>D</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-6254-2054</Identifier>
<AffiliationInfo><Affiliation>Maudsley Hospital, Denmark Hill, Camberwell, London SE5 8AZ, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kalafatis</LastName>
<ForeName>Chris</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>South London and Maudsley NHS Foundation Trust, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Taylor</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-2557-1710</Identifier>
<AffiliationInfo><Affiliation>South London and Maudsley NHS Foundation Trust, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Ther Adv Psychopharmacol</MedlineTA>
<NlmUniqueID>101555693</NlmUniqueID>
<ISSNLinking>2045-1253</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse effects</Keyword>
<Keyword MajorTopicYN="N">drug-interactions</Keyword>
<Keyword MajorTopicYN="N">psychotropic drugs</Keyword>
<Keyword MajorTopicYN="N">treatment COVID-19</Keyword>
</KeywordList>
<CoiStatement>Conflict of interest statement: The authors declare that there is no conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32612804</ArticleId>
<ArticleId IdType="doi">10.1177/2045125320935306</ArticleId>
<ArticleId IdType="pii">10.1177_2045125320935306</ArticleId>
<ArticleId IdType="pmc">PMC7309390</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Mar 26;368:m1252</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217607</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chin Med J (Engl). 2020 May 5;133(9):1132-1134</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32149772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Pharm Sin B. 2020 Apr 20;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32318327</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Engineering (Beijing). 2020 Mar 18;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32346491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2014 Oct;110:94-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25108173</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Mar 24;368:m1206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32209549</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Apr 4;395(10230):1111</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220278</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32164085</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 24;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32208486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 3;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32125362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001251 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001251 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32612804
   |texte=   Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32612804" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.

Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki